Table 1.
Clinical and pathological data
| Clinical data | Pathological data | |||
|---|---|---|---|---|
| Baseline | Surgery-related | ICI therapy-related | Oncological outcome | |
| Age | OR note (including any intraoperative events) | Dosage | Overall survival | Pathological TNM staging |
| Sex | EBL | Cycle | Progression-free survival | Cell type |
| Height | Surgical morbidity (according to CDC) | Toxicities (graded by CTCAE v5.0) | Objective response rate (according to RECIST v1.1) | ISUP nuclear grade |
| Weight | Total administration periods | |||
| BMI | Cause of discontinuation | |||
| BSA | ||||
| KPS | ||||
| IMDC risk feature | ||||
| Clinical TNM staging | ||||
| Metastatic sites | ||||
BMI body mass index, BSA body surface area, CDC Clavien–Dindo classification, CTCAE Common Terminology Criteria for Adverse Events, EBL estimated blood loss, IMDC International mRCC Database Consortium, ISUP International Society of Urologic Pathologists, KPS Karnofsky Performance Status, OR operating room, RECIST Response Evaluation Criteria for Solid Tumors